People

Jamie T. Wisz

Partner

Wisz, Jamie T.

Jamie Wisz focuses her practice on patent prosecution, USPTO proceedings, litigation, counseling, and patent policy work in the fields of biotechnology and pharmaceuticals. Her experience includes patent drafting and prosecution, portfolio management, patentability assessments, freedom-to-operate analyses, due diligence and pre-litigation investigations. Ms. Wisz's USPTO practice includes participation in reissues, reexaminations and inter partes reviews.

Ms. Wisz also has extensive experience in all aspects of intellectual property litigation, including taking and defending depositions, working with experts, and representing clients in trials and arbitration proceedings and appeals.

Prior to joining the firm, Ms. Wisz interned as a biological and economic analyst for the Central Intelligence Agency. She received her JD from Harvard Law School, where she was line editor for the Harvard Journal of Law and Technology. She received an AB in Biology, magna cum laude, from Duke University where she was elected to Phi Beta Kappa.

Ms. Wisz is admitted to practice in the District of Columbia, the state of Maryland, and before the United State Patent and Trademark Office and United States Court of Appeals for the Federal Circuit.

Publications & News

View

April 3, 2017

Practice Tips for Patentees Asserting Method-of-Treatment Claims Involving Divided Infringement

In this article published by BNA's Patent, Trademark and Copyright Journal, Kevin Prussia, Jamie Wisz and Steven Horn detail tips for patentees asserting method-of-treatment claims involving divided infringement.

December 6, 2013

House Passes Patent Litigation Bill

On December 5, 2013, the House of Representatives passed the Innovation Act (H.R. 3309) (the “Act”) by a vote of 325-91. The Act proposes several changes to the patent litigation system such as enhanced pleading requirements, fee shifting, discovery limits, patent ownership disclosures, and stays of customer suits.

June 13, 2013

Supreme Court Holds Myriad’s "Naturally Occurring" DNA Claims Not Patentable

In a unanimous decision with potentially widespread ramifications, the US Supreme Court held today that “[a] naturally occurring DNA segment is a product of nature and not patent eligible merely because it has been isolated, but cDNA is patent eligible because it is not naturally occurring.”

February 25, 2011

WilmerHale Achieves Record-Breaking Patent Ruling Reversal for Abbott Laboratories

November 17, 2010

WilmerHale Announces 2011 Partner and Special Counsel Promotions

WilmerHale is pleased to announce the 16 lawyers who will be elevated to partner and special counsel, effective January 1, 2011. They represent all five legal departments, across five of the firm's offices, and serve clients in the technology, life sciences, financial services and other areas of greatest challenge, complexity and importance.

July 1, 2010

The Government is Here to Help IP Rightholders

January 1, 2009

WilmerHale Names New Partners and Counsel for 2009

We are pleased to announce the elevation of our new partners and counsel.

October 1, 2007

Patent Reform/Repercussions to Be Watched

An article by Donna Meuth, Shann Kerner and Jamie Wisz Appearing in Women’s Business

Speaking Engagements

Recent Highlights

  • Representing a biotechnology client in an inter partes review
  • Representing a pharmaceutical company in a Hatch Waxman patent infringement case involving a treatment for HIV
  • Representing a biotechnology client in a patent ownership and trade secrets dispute that resulted in a favorable judgment after a trial before the Delaware Chancery Court
  • Managing a patent portfolio, including small molecules, biotechnology, and medical devices, for a university client
  • Successfully obtaining a stay of a patent infringement action against a pharmaceutical company pending reexamination of the asserted patent
  • Representing a pharmaceutical company in a patent infringement action involving an ANDA Paragraph IV certification concerning a treatment for Parkinson's Disease. After a bench trial, the Court issued a ruling from the bench that the opposing party had failed to carry its burden of proving that the asserted patent was invalid.

Professional Activities

Ms. Wisz is a member of the American Bar Association, the American Intellectual Property Law Association, Patent Trial and Appeal Board (PTAB) Bar Association and Women in Bio.

Practices

Skip Navigation Links.

Education

JD, Harvard Law School

AB, Biology, magna cum laude, Duke University, Phi Beta Kappa

Bar Admissions

District of Columbia

Maryland

United States Patent and Trademark Office

Skip Navigation Links.